ResVita Bio is a synthetic biology startup developing treatments for skin diseases. Leveraging the unique capabilities of topical genetically engineered bacteria, our platform is designed to produce and deliver therapeutic proteins directly to affected areas, offering a dynamic and sustained approach to treatment. This method circumvents the challenges associated with traditional protein therapies, such as stability and short half-lives, by establishing a living system that can continuously synthesize and secrete therapeutic agents. ResVita Bio's cutting-edge platform promises to transform treatments for a range of conditions, beginning with the rare skin disease Netherton Syndrome and Severe Atopic Dermatitis.
Chief Executive Officer
Co-Founder & Board Member
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.